Cargando…

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors

(68)Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumor (NET) detection and localization. However, the optimal peptide mass and radioactivity ranges for (68)Ga-satoreotide trizoxetan have not yet been esta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Virgolini, Irene, Bahri, Shadfar, Kjaer, Andreas, Grønbæk, Henning, Iversen, Peter, Carlsen, Esben A., Loft, Mathias, Knigge, Ulrich, Maffey-Steffan, Johanna, Powell, Christine, Miller, Colin G., Rohban, Thomas, McEwan, Sandy, Czernin, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2022
Materias:	Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978200/ https://www.ncbi.nlm.nih.gov/pubmed/34215673 http://dx.doi.org/10.2967/jnumed.121.261936

Ejemplares similares

A novel read methodology to evaluate the optimal dose of (68)Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial
por: Miller, Colin G., et al.
Publicado: (2021)

A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
por: Wild, Damian, et al.
Publicado: (2023)

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
por: Ilett, Emma Elizabeth, et al.
Publicado: (2015)

Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
por: Binderup, Tina, et al.
Publicado: (2013)

First-in-Human Study of [(68)Ga]Ga-NODAGA-E[c(RGDyK)](2) PET for Integrin α(v)β(3) Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability
por: Clausen, Malene Martini, et al.
Publicado: (2022)

The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
por: Maffey-Steffan, Johanna, et al.
Publicado: (2019)

Initial Experience with (64)Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET
por: Loft, Mathias, et al.
Publicado: (2021)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
por: Ali, Abir Salwa, et al.
Publicado: (2017)

Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT
por: Kaemmerer, Daniel, et al.
Publicado: (2011)

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
por: Ali, Abir Salwa, et al.
Publicado: (2018)

A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms
por: Carlsen, Esben Andreas, et al.
Publicado: (2022)

Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
por: Komek, Halil, et al.
Publicado: (2019)

Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours
por: Martini, Caroline, et al.
Publicado: (2016)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
por: Oberg, Kjell, et al.
Publicado: (2016)

Clinical and Prognostic Value of PET/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Zhang, Panpan, et al.
Publicado: (2018)

Clinical features of gastroenteropancreatic tumours
por: Gut, Paweł, et al.
Publicado: (2015)

MON-059 Acute Hyponatremia Following Computed Tomography Radiocontrast in a Pediatric Patient
por: Chiu, Harvey Kenn, et al.
Publicado: (2020)

Long-Term Survival and Value of (18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with (177)Lu-DOTATATE
por: Rodrigues, Margarida, et al.
Publicado: (2021)

Clinicopathologic analysis of primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma; A ten year retrospective study of 68 cases at Moffit Cancer Center
por: Bukhari, Mulazim Hussain, et al.
Publicado: (2020)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
por: Crabtree, Judy S.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
por: Shi, Chanjuan, et al.
Publicado: (2022)

Liver transplantation in gastroenteropancreatic neuroendocrine tumors
por: Fernandes, Eduardo de Souza M., et al.
Publicado: (2023)

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
por: McClellan, Kristen, et al.
Publicado: (2022)

Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients
por: Olsen, Ingrid Holst, et al.
Publicado: (2015)

Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors
por: Kjaer, Andreas, et al.
Publicado: (2015)

Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors
por: Gallicchio, Rosj, et al.
Publicado: (2023)

Dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
por: Chan, David L., et al.
Publicado: (2022)

Safety, tolerability and clinical implementation of ‘ready-to-use’ (68)gallium-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
por: Manoharan, Prakash, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lajm6lmregc5jvle88maoct3he